Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Core-g28v2 60mer mRNA vaccine
- Development stage
- Phase 1
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Core-g28v2 60mer mRNA vaccine (mRNA-1644v2-Core) is an investigational mRNA-based HIV vaccine candidate designed as a boost immunogen in a sequential vaccination strategy to induce broadly neutralizing antibody (bnAb) responses against HIV. The approach uses germline-targeting prime and boost immunogens to guide B-cell maturation toward bnAb development. The Core-g28v2 60mer is delivered via Moderna’s proprietary lipid nanoparticle-formulated mRNA platform. It was developed through collaboration between IAVI, Scripps Research, and Moderna, with support from the Bill & Melinda Gates Foundation and other partners. The primary indication is prevention of HIV infection; it is currently being evaluated in Phase 1 clinical trials in healthy adults[3][5][6][7].
- Other names
- Core-g28v2 60merCore-g-28v2 60merCore-g 28v2 60mer
02
Targets
Env (HIV-1 envelope glycoprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on Core-g28v2 60mer mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Core-g28v2 60mer mRNA vaccine.